# LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

> **NCT01397097** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 766 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** LNG-IUS (BAY 86-5028)
- **DRUG:** 68 mg etonorgestrel implant for subdermal use (Nexplanon)

## Key facts

- **NCT ID:** NCT01397097
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-06
- **Final completion:** 2015-04
- **Target enrollment:** 766 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397097, "LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01397097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*